ArticleCureus2026
Evaluation of the Efficacy and Tolerability of Bedaquiline in Drug-Resistant Tuberculosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultidrug-resistant tuberculosis (TB) poses a serious threat to public health globally because of limited treatment options and high levels of antimicrobial resistance. Bedaquiline is an important component of contemporary multidrug treatment regimens for drug-resistant TB. This study aimed to evaluate treatment outcomes and tolerability among patients receiving a bedaquiline-containing regimen, including sputum conversion, laboratory parameters, adverse drug reactions (ADRs), and treatment compliance. MATERIALS AND
methodsThe study was a hospital-based prospective observational study conducted among 64 patients with drug-resistant TB who attended the drug-resistant TB clinic at Zydus Medical College and Hospital, Dahod, from April 2024 to September 2025. Patients on a bedaquiline-based regimen were followed up monthly to assess sputum conversion, laboratory tests, ADRs, and treatment compliance.
resultsAmong 64 patients with drug-resistant TB, sputum conversion was achieved in 61 (95.3%), with no significant association between conversion and baseline demographic or clinical characteristics (all p > 0.05). Universal rifampicin resistance (100%) and high levels of isoniazid resistance were observed, whereas susceptibility was observed in 98.4% of isolates to injectable anti-TB drugs and in 64.1% to moxifloxacin. These in vitro drug susceptibility findings should not be interpreted as evidence of comparative clinical efficacy. Follow-up demonstrated preserved renal function, with mild but significant changes in liver function and electrolytes, whereas nausea (13, 20.3%) and electrolyte abnormalities (15, 23.4%) were the most frequent ADRs.
conclusionsA high sputum conversion rate of 95.3% (61/64) was observed during follow-up among patients receiving a bedaquiline-containing multidrug regimen. Most reported adverse events were mild; however, biochemical changes and QT prolongation were observed and require continued clinical monitoring. Given the prospective observational design, the absence of a comparator group, the concomitant use of multiple anti-TB drugs, and the limited follow-up duration, the independent contribution of bedaquiline to the observed treatment outcomes, as well as its long-term efficacy and safety, cannot be determined from the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.